Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No.9S). S152-S154.
|
Text
PIIS1556086418308153.pdf Download (160kB) | Preview |
Official URL: https://doi.org/10.1016/j.jtho.2018.07.020
| Item Type: | Article |
|---|---|
| Additional Information: | IASLC Latin American Conference on Lung Cancer |
| Uncontrolled Keywords: | chemotherapy, KEYNOTE-042, programmed death ligand 1 (PD-L1), pembrolizumab |
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 04 May 2020 10:55 |
| Last Modified: | 04 May 2020 10:55 |
| URI: | http://repo.dma.dp.ua/id/eprint/5298 |
Actions (login required)
 |
View Item |
